Single-product biotech math is brutal: if the lead asset fails, the stock can lose half its value in an afternoon. That is exactly what happened to Neumora, which collapsed roughly 47% on June 15, 2026 when its depression drug missed in two Phase 3 trials at once.
By Ruslan Averin.
This is Ruslan Averin's NMRA stock analysis — a binary clinical readout that broke the wrong way.
What failed
Neumora's KOASTAL-2 and KOASTAL-3 studies tested navacaprant in major depressive disorder. Both missed the primary and key secondary endpoints. The company is discontinuing the program entirely — there is no salvage path being pitched here.
The data tells the whole story
| Metric | Value |
|---|---|
| Stock move, June 15 | ~−46.6% |
| KOASTAL-2 MADRS delta (80 mg) | −0.3 vs placebo |
| KOASTAL-3 MADRS delta | +0.7 (worse than placebo) |
| Workforce reduction | ~35% |
| Cash runway | into Q3 2027 |
A MADRS difference near zero — and in one arm on the wrong side of zero — is not a signal you reformulate around. It is a discontinuation.
My read
The sole comfort is the balance sheet: amended loan terms and runway into 2027 buy time for NMRA-511, NMRA-898 and NMRA-215. But the market just repriced the company as a pipeline of early-stage shots on goal, not a late-stage story. That is a different, smaller valuation.
Bottom line
When a binary readout fails, you find out fast what the rest of the pipeline is worth. I do not hold the shares and am not telling anyone to buy or sell — this is analysis, not advice.